



US009687160B2

(12) **United States Patent**  
**Kiani**

(10) **Patent No.:** **US 9,687,160 B2**  
(45) **Date of Patent:** **Jun. 27, 2017**

(54) **CONGENITAL HEART DISEASE MONITOR**

USPC ..... 600/300, 301, 310, 323, 340, 473, 476;  
356/41

(71) Applicant: **MASIMO CORPORATION**, Irvine,  
CA (US)

See application file for complete search history.

(72) Inventor: **Massi Joe E. Kiani**, Laguna Niguel,  
CA (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignee: **Masimo Corporation**, Irvine, CA (US)

4,869,253 A \* 9/1989 Craig, Jr. .... A61B 5/7207  
600/323

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 361 days.

4,960,128 A 10/1990 Gordon et al.  
4,964,408 A 10/1990 Hink et al.

(Continued)

FOREIGN PATENT DOCUMENTS

(21) Appl. No.: **13/907,638**

WO WO 2013/103885 7/2013

(22) Filed: **May 31, 2013**

OTHER PUBLICATIONS

(65) **Prior Publication Data**

US 2013/0331670 A1 Dec. 12, 2013

US 8,845,543, 09/2014, Diab et al. (withdrawn)  
(Continued)

**Related U.S. Application Data**

(63) Continuation of application No. 11/858,053, filed on  
Sep. 19, 2007, now Pat. No. 8,457,707.

*Primary Examiner* — Eric Winakur

*Assistant Examiner* — Chu Chuan (JJ) Liu

(60) Provisional application No. 60/846,160, filed on Sep.  
20, 2006.

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson  
& Bear, LLP

(51) **Int. Cl.**

**A61B 5/1455** (2006.01)

**A61B 5/0205** (2006.01)

**A61B 5/024** (2006.01)

**A61B 5/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61B 5/0205** (2013.01); **A61B 5/02416**  
(2013.01); **A61B 5/14551** (2013.01); **A61B**  
**5/6826** (2013.01); **A61B 5/6829** (2013.01);  
**A61B 5/6838** (2013.01); **A61B 5/7275**  
(2013.01); **A61B 5/7278** (2013.01);  
(Continued)

(58) **Field of Classification Search**


CPC ..... A61B 5/1455; A61B 5/14551; A61B  
5/14552; A61B 5/0059; A61B 5/145

(57)

**ABSTRACT**

A congenital heart disease monitor utilizes a sensor capable of emitting multiple wavelengths of optical radiation into a tissue site and detecting the optical radiation after attenuation by pulsatile blood flowing within the tissue site. A patient monitor is capable of receiving a sensor signal corresponding to the detected optical radiation and calculating at least one physiological parameter in response. The physiological parameter is measured at a baseline site and a comparison site and a difference in these measurements is calculated. A potential congenital heart disease condition is indicated according to the measured physiological parameter at each of the sites or the calculated difference in the measured physiological parameter between the sites or both.

**11 Claims, 10 Drawing Sheets**



## (52) U.S. CL.

CPC ..... *A61B 5/7282* (2013.01); *A61B 5/742*  
(2013.01); *A61B 5/02055* (2013.01); *A61B*  
*2560/0276* (2013.01)

## (56) References Cited

## U.S. PATENT DOCUMENTS

5,041,187 A	8/1991	Hink et al.	6,144,868 A	11/2000	Parker
5,069,213 A	12/1991	Polczynski	6,151,516 A	11/2000	Kiani-Azarbayjany et al.
5,078,714 A *	1/1992	Katims ..... 606/38	6,152,754 A	11/2000	Gerhardt et al.
5,163,438 A	11/1992	Gordon et al.	6,157,850 A	12/2000	Diab et al.
5,319,355 A	6/1994	Russek	6,165,005 A	12/2000	Mills et al.
5,337,744 A	8/1994	Branigan	6,184,521 B1	2/2001	Coffin, IV et al.
5,341,805 A	8/1994	Stavridi et al.	6,206,830 B1	3/2001	Diab et al.
D353,195 S	12/1994	Savage et al.	6,229,856 B1	5/2001	Diab et al.
D353,196 S	12/1994	Savage et al.	6,232,609 B1	5/2001	Snyder et al.
5,377,676 A	1/1995	Vari et al.	6,236,872 B1	5/2001	Diab et al.
5,398,682 A *	3/1995	Lynn ..... A61B 5/14551 600/335	6,241,683 B1	6/2001	Macklem et al.
D359,546 S	6/1995	Savage et al.	6,253,097 B1	6/2001	Aronow et al.
5,431,170 A	7/1995	Mathews	6,256,523 B1	7/2001	Diab et al.
D361,840 S	8/1995	Savage et al.	6,263,222 B1	7/2001	Diab et al.
D362,063 S	9/1995	Savage et al.	6,278,522 B1	8/2001	Lepper, Jr. et al.
5,452,717 A	9/1995	Branigan et al.	6,280,213 B1	8/2001	Tobler et al.
D363,120 S	10/1995	Savage et al.	6,285,896 B1	9/2001	Tobler et al.
5,456,252 A	10/1995	Vari et al.	6,301,493 B1	10/2001	Marro et al.
5,479,934 A	1/1996	Imran	6,317,627 B1	11/2001	Ennen et al.
5,482,036 A	1/1996	Diab et al.	6,321,100 B1	11/2001	Parker
5,490,505 A	2/1996	Diab et al.	6,321,110 B1	11/2001	Ito et al.
5,494,043 A	2/1996	O'Sullivan et al.	6,325,761 B1	12/2001	Jay
5,533,511 A	7/1996	Kaspari et al.	6,334,065 B1 *	12/2001	Al-Ali ..... A61B 5/746 600/323
5,534,851 A	7/1996	Russek	6,343,224 B1	1/2002	Parker
5,561,275 A	10/1996	Savage et al.	6,349,228 B1	2/2002	Kiani et al.
5,562,002 A	10/1996	Lalin	6,360,114 B1	3/2002	Diab et al.
5,590,649 A	1/1997	Caro et al.	6,368,283 B1	4/2002	Xu et al.
5,602,924 A	2/1997	Durand et al.	6,371,921 B1	4/2002	Caro et al.
5,632,272 A	5/1997	Diab et al.	6,377,829 B1	4/2002	Al-Ali
5,638,816 A	6/1997	Kiani-Azarbayjany et al.	6,388,240 B2	5/2002	Schulz et al.
5,638,818 A	6/1997	Diab et al.	6,397,091 B2	5/2002	Diab et al.
5,645,440 A	7/1997	Tobler et al.	6,430,437 B1	8/2002	Marro
5,685,299 A	11/1997	Diab et al.	6,430,525 B1	8/2002	Weber et al.
D393,830 S	4/1998	Tobler et al.	6,463,311 B1	10/2002	Diab
5,743,262 A	4/1998	Lepper, Jr. et al.	6,470,199 B1	10/2002	Kopotic et al.
5,758,644 A	6/1998	Diab et al.	6,501,975 B2	12/2002	Diab et al.
5,760,910 A	6/1998	Lepper, Jr. et al.	6,505,059 B1	1/2003	Kollias et al.
5,769,785 A	6/1998	Diab et al.	6,515,273 B2	2/2003	Al-Ali
5,782,757 A	7/1998	Diab et al.	6,519,487 B1	2/2003	Parker
5,785,659 A	7/1998	Caro et al.	6,525,386 B1	2/2003	Mills et al.
5,791,347 A	8/1998	Flaherty et al.	6,526,300 B1	2/2003	Kiani et al.
5,810,734 A	9/1998	Caro et al.	6,541,756 B2	4/2003	Schulz et al.
5,823,950 A	10/1998	Diab et al.	6,542,764 B1	4/2003	Al-Ali et al.
5,830,131 A	11/1998	Caro et al.	6,580,086 B1	6/2003	Schulz et al.
5,833,618 A	11/1998	Caro et al.	6,584,336 B1	6/2003	Ali et al.
5,860,919 A	1/1999	Kiani-Azarbayjany et al.	6,595,316 B2	7/2003	Cybulski et al.
5,890,929 A	4/1999	Mills et al.	6,597,932 B2	7/2003	Tian et al.
5,904,654 A	5/1999	Wohlmann et al.	6,597,933 B2	7/2003	Kiani et al.
5,919,134 A	7/1999	Diab	6,606,511 B1	8/2003	Ali et al.
5,934,277 A *	8/1999	Mortz ..... A61B 5/14551 600/323	6,632,181 B2	10/2003	Flaherty et al.
5,934,925 A	8/1999	Tobler et al.	6,639,668 B1	10/2003	Trepagnier
5,940,182 A	8/1999	Lepper, Jr. et al.	6,640,116 B2	10/2003	Diab
5,995,855 A	11/1999	Kiani et al.	6,643,530 B2	11/2003	Diab et al.
5,997,343 A	12/1999	Mills et al.	6,650,917 B2	11/2003	Diab et al.
6,002,952 A	12/1999	Diab et al.	6,654,624 B2	11/2003	Diab et al.
6,011,986 A	1/2000	Diab et al.	6,658,276 B2	12/2003	Kiani et al.
6,027,452 A	2/2000	Flaherty et al.	6,661,161 B1	12/2003	Lanzo et al.
6,036,642 A	3/2000	Diab et al.	6,671,531 B2	12/2003	Al-Ali et al.
6,045,509 A	4/2000	Caro et al.	6,678,543 B2	1/2004	Diab et al.
6,067,462 A	5/2000	Diab et al.	6,684,090 B2	1/2004	Ali et al.
6,081,735 A	6/2000	Diab et al.	6,684,091 B2	1/2004	Parker
6,083,172 A	7/2000	Baker, Jr. et al.	6,697,656 B1	2/2004	Al-Ali
6,088,607 A	7/2000	Diab et al.	6,697,657 B1	2/2004	Shehada et al.
6,110,522 A	8/2000	Lepper, Jr. et al.	6,697,658 B2	2/2004	Al-Ali
6,124,597 A	9/2000	Shehada	RE38,476 E	3/2004	Diab et al.
6,128,521 A	10/2000	Marro et al.	6,699,194 B1	3/2004	Diab et al.
6,129,675 A	10/2000	Jay	6,714,804 B2	3/2004	Al-Ali et al.
			RE38,492 E	4/2004	Diab et al.
			6,721,582 B2	4/2004	Trepagnier et al.
			6,721,585 B1	4/2004	Parker
			6,725,075 B2	4/2004	Al-Ali
			6,728,560 B2	4/2004	Kollias et al.
			6,735,459 B2	5/2004	Parker
			6,745,060 B2	6/2004	Diab et al.
			6,760,607 B2	7/2004	Al-Ali
			6,770,028 B1	8/2004	Ali et al.
			6,771,994 B2	8/2004	Kiani et al.
			6,792,300 B1	9/2004	Diab et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,813,511 B2	11/2004	Diab et al.	7,428,432 B2	9/2008	Ali et al.
6,816,741 B2	11/2004	Diab	7,438,683 B2	10/2008	Al-Ali et al.
6,822,564 B2	11/2004	Al-Ali	7,440,787 B2	10/2008	Diab
6,826,419 B2	11/2004	Diab et al.	7,454,240 B2	11/2008	Diab et al.
6,830,711 B2	12/2004	Mills et al.	7,467,002 B2	12/2008	Weber et al.
6,850,787 B2	2/2005	Weber et al.	7,469,157 B2	12/2008	Diab et al.
6,850,788 B2	2/2005	Al-Ali	7,471,969 B2	12/2008	Diab et al.
6,852,083 B2	2/2005	Caro et al.	7,471,971 B2	12/2008	Diab et al.
6,861,639 B2	3/2005	Al-Ali	7,483,729 B2	1/2009	Al-Ali et al.
6,898,452 B2	5/2005	Al-Ali et al.	7,483,730 B2	1/2009	Diab et al.
6,920,345 B2	7/2005	Al-Ali et al.	7,489,958 B2	2/2009	Diab et al.
6,931,268 B1	8/2005	Kiani-Azarbayjany et al.	7,496,391 B2	2/2009	Diab et al.
6,934,570 B2	8/2005	Kiani et al.	7,496,393 B2	2/2009	Diab et al.
6,939,305 B2	9/2005	Flaherty et al.	D587,657 S	3/2009	Al-Ali et al.
6,943,348 B1	9/2005	Coffin, IV	7,499,741 B2	3/2009	Diab et al.
6,950,687 B2	9/2005	Al-Ali	7,499,835 B2	3/2009	Weber et al.
6,961,598 B2	11/2005	Diab	7,500,950 B2	3/2009	Al-Ali et al.
6,970,792 B1	11/2005	Diab	7,509,154 B2	3/2009	Diab et al.
6,979,812 B2	12/2005	Al-Ali	7,509,494 B2	3/2009	Al-Ali
6,985,764 B2	1/2006	Mason et al.	7,510,849 B2	3/2009	Schurman et al.
6,993,371 B2	1/2006	Kiani et al.	7,526,328 B2	4/2009	Diab et al.
6,996,427 B2	2/2006	Ali et al.	7,530,942 B1	5/2009	Diab
6,999,904 B2	2/2006	Weber et al.	7,530,949 B2	5/2009	Al Ali et al.
7,003,338 B2	2/2006	Weber et al.	7,530,955 B2	5/2009	Diab et al.
7,003,339 B2	2/2006	Diab et al.	7,563,110 B2	7/2009	Al-Ali et al.
7,015,451 B2	3/2006	Dalke et al.	7,596,398 B2	9/2009	Al-Ali et al.
7,024,233 B2	4/2006	Ali et al.	7,618,375 B2	11/2009	Flaherty
7,027,849 B2	4/2006	Al-Ali	D606,659 S	12/2009	Kiani et al.
7,030,749 B2	4/2006	Al-Ali	7,647,083 B2	1/2010	Al-Ali et al.
7,039,449 B2	5/2006	Al-Ali	D609,193 S	2/2010	Al-Ali et al.
7,041,060 B2	5/2006	Flaherty et al.	D614,305 S	4/2010	Al-Ali et al.
7,044,918 B2	5/2006	Diab	RE41,317 E	5/2010	Parker
7,067,893 B2	6/2006	Mills et al.	7,729,733 B2	6/2010	Al-Ali et al.
7,096,052 B2	8/2006	Mason et al.	7,734,320 B2	6/2010	Al-Ali
7,096,054 B2	8/2006	Abdul-Hafiz et al.	7,761,127 B2	7/2010	Al-Ali et al.
7,132,641 B2	11/2006	Schulz et al.	7,761,128 B2	7/2010	Al-Ali et al.
7,142,901 B2	11/2006	Kiani et al.	7,764,982 B2	7/2010	Dalke et al.
7,149,561 B2	12/2006	Diab	D621,516 S	8/2010	Kiani et al.
7,186,966 B2	3/2007	Al-Ali	7,791,155 B2	9/2010	Diab
7,190,261 B2	3/2007	Al-Ali	7,801,581 B2	9/2010	Diab
7,215,984 B2	5/2007	Diab et al.	7,822,452 B2	10/2010	Schurman et al.
7,215,986 B2	5/2007	Diab et al.	RE41,912 E	11/2010	Parker
7,221,971 B2	5/2007	Diab	7,844,313 B2	11/2010	Kiani et al.
7,225,006 B2	5/2007	Al-Ali et al.	7,844,314 B2	11/2010	Al-Ali
7,225,007 B2	5/2007	Al-Ali	7,844,315 B2	11/2010	Al-Ali
RE39,672 E	6/2007	Shehada et al.	7,865,222 B2	1/2011	Weber et al.
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	7,873,497 B2	1/2011	Weber et al.
7,245,953 B1	7/2007	Parker	7,880,606 B2	2/2011	Al-Ali
7,254,429 B2	8/2007	Schurman et al.	7,880,626 B2	2/2011	Al-Ali et al.
7,254,431 B2	8/2007	Al-Ali	7,891,355 B2	2/2011	Al-Ali et al.
7,254,433 B2	8/2007	Diab et al.	7,894,868 B2	2/2011	Al-Ali et al.
7,254,434 B2	8/2007	Schulz et al.	7,899,507 B2	3/2011	Al-Ali et al.
7,272,425 B2	9/2007	Al-Ali	7,899,518 B2	3/2011	Trepagnier et al.
7,274,955 B2	9/2007	Kiani et al.	7,904,132 B2	3/2011	Weber et al.
D554,263 S	10/2007	Al-Ali	7,909,772 B2	3/2011	Popov et al.
7,280,858 B2	10/2007	Al-Ali et al.	7,910,875 B2	3/2011	Al-Ali
7,289,835 B2	10/2007	Mansfield et al.	7,919,713 B2	4/2011	Al-Ali et al.
7,292,883 B2	11/2007	De Felice et al.	7,937,128 B2	5/2011	Al-Ali
7,295,866 B2	11/2007	Al-Ali	7,937,129 B2	5/2011	Mason et al.
7,328,053 B1	2/2008	Diab et al.	7,937,130 B2	5/2011	Diab et al.
7,332,784 B2	2/2008	Mills et al.	7,941,199 B2	5/2011	Kiani
7,340,287 B2	3/2008	Mason et al.	7,942,824 B1	5/2011	Kayyali et al.
7,341,559 B2	3/2008	Schulz et al.	7,951,086 B2	5/2011	Flaherty et al.
7,343,186 B2	3/2008	Lamego et al.	7,957,780 B2	6/2011	Lamego et al.
D566,282 S	4/2008	Al-Ali et al.	7,962,188 B2	6/2011	Kiani et al.
7,355,512 B1	4/2008	Al-Ali	7,962,190 B1	6/2011	Diab et al.
7,356,365 B2	4/2008	Schurman	7,976,472 B2	7/2011	Kiani
7,371,981 B2	5/2008	Abdul-Hafiz	7,988,637 B2	8/2011	Diab
7,373,193 B2	5/2008	Al-Ali et al.	7,990,382 B2	8/2011	Kiani
7,373,194 B2	5/2008	Weber et al.	7,991,446 B2	8/2011	Al-Ali et al.
7,376,453 B1	5/2008	Diab et al.	8,000,761 B2	8/2011	Al-Ali
7,377,794 B2	5/2008	Al Ali et al.	8,008,088 B2	8/2011	Bellott et al.
7,377,899 B2	5/2008	Weber et al.	RE42,753 E	9/2011	Kiani-Azarbayjany et al.
7,383,070 B2	6/2008	Diab et al.	8,019,400 B2	9/2011	Diab et al.
7,415,297 B2	8/2008	Al-Ali et al.	8,028,701 B2	10/2011	Al-Ali et al.
			8,029,765 B2	10/2011	Bellott et al.
			8,036,728 B2	10/2011	Diab et al.
			8,046,040 B2	10/2011	Ali et al.
			8,046,041 B2	10/2011	Diab et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,046,042	B2	10/2011	Diab et al.	8,560,032	B2	10/2013	Al-Ali et al.
8,048,040	B2	11/2011	Kiani	8,560,034	B1	10/2013	Diab et al.
8,050,728	B2	11/2011	Al-Ali et al.	8,570,167	B2	10/2013	Al-Ali
RE43,169	E	2/2012	Parker	8,570,503	B2	10/2013	Vo et al.
8,118,620	B2	2/2012	Al-Ali et al.	8,571,617	B2	10/2013	Reichgott et al.
8,126,528	B2	2/2012	Diab et al.	8,571,618	B1	10/2013	Lamego et al.
8,128,572	B2	3/2012	Diab et al.	8,571,619	B2	10/2013	Al-Ali et al.
8,130,105	B2	3/2012	Al-Ali et al.	8,577,431	B2	11/2013	Lamego et al.
8,145,287	B2	3/2012	Diab et al.	8,581,732	B2	11/2013	Al-Ali et al.
8,150,487	B2	4/2012	Diab et al.	8,584,345	B2	11/2013	Al-Ali et al.
8,175,672	B2	5/2012	Parker	8,588,880	B2	11/2013	Abdul-Hafiz et al.
8,180,420	B2	5/2012	Diab et al.	8,600,467	B2	12/2013	Al-Ali et al.
8,182,443	B1	5/2012	Kiani	8,606,342	B2	12/2013	Diab
8,185,180	B2	5/2012	Diab et al.	8,626,255	B2	1/2014	Al-Ali et al.
8,190,223	B2	5/2012	Al-Ali et al.	8,630,691	B2	1/2014	Lamego et al.
8,190,227	B2	5/2012	Diab et al.	8,634,889	B2	1/2014	Al-Ali et al.
8,203,438	B2	6/2012	Kiani et al.	8,641,631	B2	2/2014	Sierra et al.
8,203,704	B2	6/2012	Merritt et al.	8,652,060	B2	2/2014	Al-Ali
8,224,411	B2	7/2012	Al-Ali et al.	8,663,107	B2	3/2014	Kiani
8,228,181	B2	7/2012	Al-Ali	8,666,468	B1	3/2014	Al-Ali
8,229,533	B2	7/2012	Diab et al.	8,667,967	B2	3/2014	Al-Ali et al.
8,233,955	B2	7/2012	Al-Ali et al.	8,670,811	B2	3/2014	O'Reilly
8,244,325	B2	8/2012	Al-Ali et al.	8,670,814	B2	3/2014	Diab et al.
8,255,026	B1	8/2012	Al-Ali	8,676,286	B2	3/2014	Weber et al.
8,255,027	B2	8/2012	Al-Ali et al.	8,682,407	B2	3/2014	Al-Ali
8,255,028	B2	8/2012	Al-Ali et al.	RE44,823	E	4/2014	Parker
8,260,577	B2	9/2012	Weber et al.	RE44,875	E	4/2014	Kiani et al.
8,265,723	B1	9/2012	McHale et al.	8,690,799	B2	4/2014	Telfort et al.
8,274,360	B2	9/2012	Sampath et al.	8,700,112	B2	4/2014	Kiani
8,301,217	B2	10/2012	Al-Ali et al.	8,702,627	B2	4/2014	Telfort et al.
8,310,336	B2	11/2012	Muhsin et al.	8,706,179	B2	4/2014	Parker
8,315,683	B2	11/2012	Al-Ali et al.	8,712,494	B1	4/2014	MacNeish, III et al.
RE43,860	E	12/2012	Parker	8,715,206	B2	5/2014	Telfort et al.
8,337,403	B2	12/2012	Al-Ali et al.	8,718,735	B2	5/2014	Lamego et al.
8,346,330	B2	1/2013	Lamego	8,718,737	B2	5/2014	Diab et al.
8,353,842	B2	1/2013	Al-Ali et al.	8,718,738	B2	5/2014	Blank et al.
8,355,766	B2	1/2013	MacNeish, III et al.	8,720,249	B2	5/2014	Al-Ali
8,359,080	B2	1/2013	Diab et al.	8,721,541	B2	5/2014	Al-Ali et al.
8,364,223	B2	1/2013	Al-Ali et al.	8,721,542	B2	5/2014	Al-Ali et al.
8,364,226	B2	1/2013	Diab et al.	8,723,677	B1	5/2014	Kiani
8,374,665	B2	2/2013	Lamego	8,740,792	B1	6/2014	Kiani et al.
8,385,995	B2	2/2013	Al-Ali et al.	8,754,776	B2	6/2014	Poeze et al.
8,385,996	B2	2/2013	Smith et al.	8,755,535	B2	6/2014	Telfort et al.
8,388,353	B2	3/2013	Kiani et al.	8,755,856	B2	6/2014	Diab et al.
8,399,822	B2	3/2013	Al-Ali	8,755,872	B1	6/2014	Marinow
8,401,602	B2	3/2013	Kiani	8,761,850	B2	6/2014	Lamego
8,405,608	B2	3/2013	Al-Ali et al.	8,764,671	B2	7/2014	Kiani
8,414,499	B2	4/2013	Al-Ali et al.	8,768,423	B2	7/2014	Shakespeare et al.
8,418,524	B2	4/2013	Al-Ali	8,771,204	B2	7/2014	Telfort et al.
8,423,106	B2	4/2013	Lamego et al.	8,777,634	B2	7/2014	Kiani et al.
8,428,967	B2	4/2013	Olsen et al.	8,781,543	B2	7/2014	Diab et al.
8,430,817	B1	4/2013	Al-Ali et al.	8,781,544	B2	7/2014	Al-Ali et al.
8,437,825	B2	5/2013	Dalvi et al.	8,781,549	B2	7/2014	Al-Ali et al.
8,455,290	B2	6/2013	Siskavich	8,788,003	B2	7/2014	Schurman et al.
8,457,703	B2	6/2013	Al-Ali	8,790,268	B2	7/2014	Al-Ali
8,457,707	B2	6/2013	Kiani	8,801,613	B2	8/2014	Al-Ali et al.
8,463,349	B2	6/2013	Diab et al.	8,821,397	B2	9/2014	Al-Ali et al.
8,466,286	B2	6/2013	Bellot et al.	8,821,415	B2	9/2014	Al-Ali et al.
8,471,713	B2	6/2013	Poeze et al.	8,830,449	B1	9/2014	Lamego et al.
8,473,020	B2	6/2013	Kiani et al.	8,831,700	B2	9/2014	Schurman et al.
8,483,787	B2	7/2013	Al-Ali et al.	8,840,549	B2	9/2014	Al-Ali et al.
8,489,364	B2	7/2013	Weber et al.	8,847,740	B2	9/2014	Kiani et al.
8,498,684	B2	7/2013	Weber et al.	8,849,365	B2	9/2014	Smith et al.
8,504,128	B2	8/2013	Blank et al.	8,852,094	B2	10/2014	Al-Ali et al.
8,509,867	B2	8/2013	Workman et al.	8,852,994	B2	10/2014	Wojtczuk et al.
8,515,509	B2	8/2013	Bruinsma et al.	8,868,147	B2	10/2014	Stippick et al.
8,523,781	B2	9/2013	Al-Ali	8,868,150	B2	10/2014	Al-Ali et al.
8,529,301	B2	9/2013	Al-Ali et al.	8,870,792	B2	10/2014	Al-Ali et al.
8,532,727	B2	9/2013	Ali et al.	8,886,271	B2	11/2014	Kiani et al.
8,532,728	B2	9/2013	Diab et al.	8,888,539	B2	11/2014	Al-Ali et al.
D692,145	S	10/2013	Al-Ali et al.	8,888,708	B2	11/2014	Diab et al.
8,547,209	B2	10/2013	Kiani et al.	8,892,180	B2	11/2014	Weber et al.
8,548,548	B2	10/2013	Al-Ali	8,897,847	B2	11/2014	Al-Ali
8,548,549	B2	10/2013	Schurman et al.	8,909,310	B2	12/2014	Lamego et al.
8,548,550	B2	10/2013	Al-Ali et al.	8,911,377	B2	12/2014	Al-Ali
				8,912,909	B2	12/2014	Al-Ali et al.
				8,920,317	B2	12/2014	Al-Ali et al.
				8,921,699	B2	12/2014	Al-Ali et al.
				8,922,382	B2	12/2014	Al-Ali et al.

(56)	<b>References Cited</b>		2005/0165316 A1*	7/2005	Lowery .....	A61B 5/14532 600/323
	U.S. PATENT DOCUMENTS		2008/0009754 A1*	1/2008	Chang .....	600/483
8,929,964 B2	1/2015	Al-Ali et al.	2008/0071155 A1	3/2008	Kiani	
8,942,777 B2	1/2015	Diab et al.	2008/0221464 A1	9/2008	Al-Ali	
8,948,834 B2	2/2015	Diab et al.	2009/0247984 A1	10/2009	Lamego et al.	
8,948,835 B2	2/2015	Diab	2009/0275844 A1	11/2009	Al-Ali	
8,965,471 B2	2/2015	Lamego	2010/0004518 A1	1/2010	Vo et al.	
8,983,564 B2	3/2015	Al-Ali	2010/0030040 A1	2/2010	Poeze et al.	
8,989,831 B2	3/2015	Al-Ali et al.	2011/0001605 A1	1/2011	Kiani et al.	
8,996,085 B2	3/2015	Kiani et al.	2011/0082711 A1	4/2011	Poeze et al.	
8,998,809 B2	4/2015	Kiani	2011/0105854 A1	5/2011	Kiani et al.	
9,028,429 B2	5/2015	Telfort et al.	2011/0208015 A1	8/2011	Welch et al.	
9,037,207 B2	5/2015	Al-Ali et al.	2011/0213212 A1	9/2011	Al-Ali	
9,060,721 B2	6/2015	Reichgott et al.	2011/0230733 A1	9/2011	Al-Ali	
9,066,666 B2	6/2015	Kiani	2011/0237911 A1	9/2011	Lamego et al.	
9,066,680 B1	6/2015	Al-Ali et al.	2012/0059267 A1	3/2012	Lamego et al.	
9,072,474 B2	7/2015	Al-Ali et al.	2012/0179006 A1	7/2012	Jansen et al.	
9,078,560 B2	7/2015	Schurman et al.	2012/0209082 A1	8/2012	Al-Ali	
9,084,569 B2	7/2015	Weber et al.	2012/0209084 A1	8/2012	Olsen et al.	
9,095,316 B2	8/2015	Welch et al.	2012/0227739 A1	9/2012	Kiani	
9,106,038 B2	8/2015	Telfort et al.	2012/0283524 A1	11/2012	Kiani et al.	
9,107,625 B2	8/2015	Telfort et al.	2012/0296178 A1	11/2012	Lamego et al.	
9,107,626 B2	8/2015	Al-Ali et al.	2012/0319816 A1	12/2012	Al-Ali	
9,113,831 B2	8/2015	Al-Ali	2012/0330112 A1	12/2012	Lamego et al.	
9,113,832 B2	8/2015	Al-Ali	2013/0023775 A1	1/2013	Lamego et al.	
9,119,595 B2	9/2015	Lamego	2013/0041591 A1	2/2013	Lamego	
9,131,881 B2	9/2015	Diab et al.	2013/0045685 A1	2/2013	Kiani	
9,131,882 B2	9/2015	Al-Ali et al.	2013/0046204 A1	2/2013	Lamego et al.	
9,131,883 B2	9/2015	Al-Ali	2013/0060147 A1	3/2013	Welch et al.	
9,131,917 B2	9/2015	Telfort et al.	2013/0096405 A1	4/2013	Garfio	
9,138,180 B1	9/2015	Coverston et al.	2013/0096936 A1	4/2013	Sampath et al.	
9,138,182 B2	9/2015	Al-Ali et al.	2013/0190581 A1	7/2013	Al-Ali et al.	
9,138,192 B2	9/2015	Weber et al.	2013/0197328 A1	8/2013	Diab et al.	
9,142,117 B2	9/2015	Muhsin et al.	2013/0211214 A1	8/2013	Olsen	
9,153,112 B1	10/2015	Kiani et al.	2013/0243021 A1	9/2013	Siskavich	
9,153,121 B2	10/2015	Kiani et al.	2013/0253334 A1	9/2013	Al-Ali et al.	
9,161,696 B2	10/2015	Al-Ali et al.	2013/0296672 A1	11/2013	O'Neil et al.	
9,161,713 B2	10/2015	Al-Ali et al.	2013/0317370 A1	11/2013	Dalvi et al.	
9,167,995 B2	10/2015	Lamego et al.	2013/0324808 A1	12/2013	Al-Ali et al.	
9,176,141 B2	11/2015	Al-Ali et al.	2013/0331670 A1	12/2013	Kiani	
9,186,102 B2	11/2015	Bruinsma et al.	2013/0338461 A1	12/2013	Lamego et al.	
9,192,312 B2	11/2015	Al-Ali	2014/0012100 A1	1/2014	Al-Ali et al.	
9,192,329 B2	11/2015	Al-Ali	2014/0034353 A1	2/2014	Al-Ali et al.	
9,192,351 B1	11/2015	Telfort et al.	2014/0051953 A1	2/2014	Lamego et al.	
9,195,385 B2	11/2015	Al-Ali et al.	2014/0058230 A1	2/2014	Abdul-Hafiz et al.	
9,211,072 B2	12/2015	Kiani	2014/0066783 A1	3/2014	Kiani et al.	
9,211,095 B1	12/2015	Al-Ali	2014/0077956 A1	3/2014	Sampath et al.	
9,218,454 B2	12/2015	Kiani et al.	2014/0081100 A1	3/2014	Muhsin et al.	
9,226,696 B2	1/2016	Kiani	2014/0081175 A1	3/2014	Telfort	
9,241,662 B2	1/2016	Al-Ali et al.	2014/0094667 A1	4/2014	Schurman et al.	
9,245,668 B1	1/2016	Vo et al.	2014/0100434 A1	4/2014	Diab et al.	
9,259,185 B2	2/2016	Abdul-Hafiz et al.	2014/0114199 A1	4/2014	Lamego et al.	
9,267,572 B2	2/2016	Barker et al.	2014/0120564 A1	5/2014	Workman et al.	
9,277,880 B2	3/2016	Poeze et al.	2014/0121482 A1	5/2014	Merritt et al.	
9,289,167 B2	3/2016	Diab et al.	2014/0121483 A1	5/2014	Bellott et al.	
9,295,421 B2	3/2016	Kiani et al.	2014/0127137 A1	5/2014	Lamego et al.	
9,307,928 B1	4/2016	Al-Ali et al.	2014/0129702 A1	5/2014	Al-Ali et al.	
9,323,894 B2	4/2016	Kiani	2014/0135588 A1	5/2014	Al-Ali et al.	
D755,392 S	5/2016	Hwang et al.	2014/0142401 A1	5/2014	Al-Ali et al.	
9,326,712 B1	5/2016	Kiani	2014/0163344 A1	6/2014	Al-Ali	
9,333,316 B2	5/2016	Kiani	2014/0163402 A1	6/2014	Lamego et al.	
9,339,220 B2	5/2016	Lamego et al.	2014/0166076 A1	6/2014	Kiani et al.	
9,341,565 B2	5/2016	Lamego et al.	2014/0171763 A1	6/2014	Diab	
9,351,673 B2	5/2016	Diab et al.	2014/0180038 A1	6/2014	Kiani	
9,351,675 B2	5/2016	Al-Ali et al.	2014/0180154 A1	6/2014	Sierra et al.	
9,364,181 B2	6/2016	Kiani et al.	2014/0194709 A1	7/2014	Al-Ali et al.	
9,368,671 B2	6/2016	Wojtczuk et al.	2014/0194711 A1	7/2014	Al-Ali	
9,370,325 B2	6/2016	Al-Ali et al.	2014/0194766 A1	7/2014	Al-Ali et al.	
9,370,326 B2	6/2016	McHale et al.	2014/0206963 A1	7/2014	Al-Ali	
9,370,335 B2	6/2016	Al-Ali et al.	2014/0213864 A1	7/2014	Abdul-Hafiz et al.	
9,375,185 B2	6/2016	Ali et al.	2014/0243627 A1	8/2014	Diab et al.	
9,386,953 B2	7/2016	Al-Ali	2014/0266790 A1	9/2014	Al-Ali et al.	
9,386,961 B2	7/2016	Al-Ali et al.	2014/0275808 A1	9/2014	Poeze et al.	
9,392,945 B2	7/2016	Al-Ali et al.	2014/0275835 A1	9/2014	Lamego et al.	
9,397,448 B2	7/2016	Al-Ali et al.	2014/0275871 A1	9/2014	Lamego et al.	
2004/0034293 A1	2/2004	Kimball	2014/0275872 A1	9/2014	Merritt et al.	
2004/0097797 A1	5/2004	Porges et al.	2014/0275881 A1	9/2014	Lamego et al.	
			2014/0288400 A1	9/2014	Diab et al.	

(56)

**References Cited**

## U.S. PATENT DOCUMENTS

2014/0303520 A1 10/2014 Telfort et al.  
 2014/0316228 A1 10/2014 Blank et al.  
 2014/0323825 A1 10/2014 Al-Ali et al.  
 2014/0330092 A1 11/2014 Al-Ali et al.  
 2014/0330098 A1 11/2014 Merritt et al.  
 2014/0330099 A1 11/2014 Al-Ali et al.  
 2014/0333440 A1 11/2014 Kiani  
 2014/0336481 A1 11/2014 Shakespeare et al.  
 2014/0343436 A1 11/2014 Kiani  
 2015/0018650 A1 1/2015 Al-Ali et al.  
 2015/0351697 A1 12/2015 Weber et al.  
 2015/0351704 A1 12/2015 Kiani et al.  
 2015/0359429 A1 12/2015 Al-Ali et al.  
 2015/0366472 A1 12/2015 Kiani  
 2015/0366507 A1 12/2015 Blank  
 2015/0374298 A1 12/2015 Al-Ali et al.  
 2015/0380875 A1 12/2015 Coverston et al.  
 2016/0000362 A1 1/2016 Diab et al.  
 2016/0007930 A1 1/2016 Weber et al.  
 2016/0029932 A1 2/2016 Al-Ali  
 2016/0029933 A1 2/2016 Al-Ali et al.  
 2016/0045118 A1 2/2016 Kiani  
 2016/0051205 A1 2/2016 Al-Ali et al.  
 2016/0058338 A1 3/2016 Schurman et al.  
 2016/0058347 A1 3/2016 Reichgott et al.  
 2016/0066823 A1 3/2016 Al-Ali et al.  
 2016/0066824 A1 3/2016 Al-Ali et al.  
 2016/0066879 A1 3/2016 Telfort et al.  
 2016/0072429 A1 3/2016 Kiani et al.

2016/0073967 A1 3/2016 Lamego et al.  
 2016/0081552 A1 3/2016 Wojtczuk et al.  
 2016/0095543 A1 4/2016 Telfort et al.  
 2016/0095548 A1 4/2016 Al-Ali et al.  
 2016/0103598 A1 4/2016 Al-Ali et al.  
 2016/0113527 A1 4/2016 Al-Ali et al.  
 2016/0143548 A1 5/2016 Al-Ali  
 2016/0166210 A1 6/2016 Al-Ali  
 2016/0192869 A1 7/2016 Kiani et al.  
 2016/0196388 A1 7/2016 Lamego  
 2016/0197436 A1 7/2016 Barker et al.  
 2016/0213281 A1 7/2016 Eckerbom et al.

## OTHER PUBLICATIONS

Granelli A.D., Mellander et al., "Screening for duct-dependent congenital heart disease with pulse oximetry: A critical evaluation of strategies to maximize sensitivity", *Acta Paediatrica*, 2005; 94:1590-1596, [http://www.masimo.com/pdf/Granelli\\_Article.pdf](http://www.masimo.com/pdf/Granelli_Article.pdf), 1 page downloaded and printed from the World Wide Web.  
 Koppel, Robert I et al., "Effective of Pulse Oximetry Screening for Congenital Heart Disease in Asymptomatic Newborns", *Pediatrics*, 2003, vol. 111, No. 3, 451-455.  
 PCT International Search Report and Written Opinion, dated Apr. 17, 2013, re: PCT Application No. PCT/US2013/020377, application dated Jan. 4, 2013, in 13 pages.  
 PCT Preliminary Report on Patentability, dated Jul. 8, 2014, for application No. PCT/US2013/020377 in 8 pages.

\* cited by examiner




FIG. 1




FIG. 2







FIG. 3






FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9



## CONGENITAL HEART DISEASE MONITOR

## REFERENCE TO RELATED APPLICATION

The present application is a continuation of U.S. application Ser. No. 11/858,053, filed Sep. 19, 2007, entitled "Congenital Heart Disease Monitor," which claims priority benefit under 35 U.S.C. §119(e) from U.S. Provisional Application No. 60/846,160, filed Sep. 20, 2006, entitled "Congenital Heart Disease Monitor," which is incorporated herein by reference.

## BACKGROUND OF THE INVENTION

Congenital heart disease (CHD) is relatively common, occurring in 5 to 10 of every 1,000 live births. Early diagnosis and treatment has improved outcomes in this population, but still a number of infants with CHD are sent home undiagnosed. Up to 30% of deaths due to CHD in the first year of life are due to such unrecognized cases. Several forms of CHD are the result of a patent ductus arteriosus (PDA).

FIG. 1 illustrates a fetal heart **102** and a portion of a fetal lung **104**. Prior to birth, the lung **104** is non-functional and fluid-filled. Instead, oxygenated blood is supplied to the fetus from gas-exchange in the placenta with the mother's blood supply. Specifically, oxygenated blood flows from the placenta, through the umbilical vein **106** and into the right atrium **122**. There, it flows via the foramen **124** into the left atrium **152**, where it is pumped into the left ventricle **150** and then into the aortic trunk **190**. Also, oxygenated blood is pumped from the right atrium **122** into the right ventricle **120** and directly into the descending aorta **140** via the main pulmonary artery **180** and the ductus arteriosus **130**. The purpose of the ductus arteriosus **130** is to shunt blood pumped by the right ventricle **120** past the constricted pulmonary circulation **110** and into the aorta **140**. Normally, the ductus arteriosus **130** is only patent (open) during fetal life and the first 12 to 24 hours of life in term infants. If the ductus arteriosus remains patent, however, it can contribute to duct-dependent congenital heart diseases, such as those described below.

## Patent Ductus Arteriosus

FIG. 2 illustrates a neonatal heart **202** with a patent ductus arteriosus **230**. The ductus arteriosus frequently fails to close in premature infants, allowing left-to-right shunting, where oxygenated "red" blood flows from the aorta **240** to the now unobstructed pulmonary artery **210** and recirculates through the lungs **204**. A persistent patent ductus arteriosus (PDA) results in pulmonary hyperperfusion and an enlarged right ventricle **220**, which leads to a variety of abnormal respiratory, cardiac and genitourinary symptoms.

## Persistent Pulmonary Hypertension in Neonates

As shown in FIG. 2, persistent Pulmonary Hypertension in Neonates (PPHN) is a neonatal condition with persistent elevation of pulmonary vascular resistance and pulmonary artery pressure. The pulmonary artery **210** that normally feeds oxygen depleted "blue" blood from the right ventricle **220** to the lung **204** is constricted. The back pressure from the constricted pulmonary artery **210** results in a right-to-left shunting of this oxygen depleted blood through the ductus arteriosus **230**, causing it to mix with oxygen rich "red" blood flowing through the descending aorta **240**.

## Aortic Coarctation

Also shown in FIG. 2, coarctation of the aorta is a congenital cardiac anomaly in which obstruction or narrowing occurs in the distal aortic arch **290** or proximal descend-

ing aorta **240**. It occurs as either an isolated lesion or coexisting with a variety of other congenital cardiac anomalies, such as a PDA. If the constriction is preductal, lower-trunk blood flow is supplied predominantly by the right ventricle **220** via the ductus arteriosus **230**, and cyanosis, i.e. poorly oxygenated blood, is present distal to the coarctation. If the constriction is postductal, blood supply to the lower trunk is supplied via the ascending aorta **240**.

## SUMMARY OF THE INVENTION

Once a problematic patent ductus arteriosus (PDA) is detected, closure can be effected medically with indomethacin or ibuprofen or surgically by ligation. Clinical symptoms of duct-dependent CHD, however, can vary on an hourly basis, and the required extended and inherently intermittent testing is difficult with current diagnostic techniques. These techniques include physical examination, chest x-ray, blood gas analysis, echocardiogram, or a combination of the above to detect, as an example, the soft, long, low-frequency murmur associated with a large PDA or, as another example, a retrograde flow into the main pulmonary artery.

As shown in FIG. 2, a right hand has blood circulating from the left ventricle **250** through the innominate artery **260**, which supplies the right subclavian artery (not shown). Because the innominate artery **260** is upstream from the ductus arteriosus **230**, the oxygen saturation value and plethysmograph waveform obtained from the right hand are relatively unaffected by the shunt and serve as a baseline or reference for comparison with readings from other tissue sites. Alternatively, a reference sensor can be placed on a facial site, such as an ear, the nose or the lips. These sites provide arterial oxygen saturation and a plethysmograph for blood circulating from the left ventricle **250** to the innominate artery **260**, which supplies the right common carotid artery (not shown), or to the left common carotid artery **265**.

Also shown in FIG. 2, either foot has blood supplied from the descending aorta **240**. A PDA **230** affects both the oxygen saturation and the blood flow in the descending aorta **240**. As stated above, the PDA **230** causes oxygen-depleted blood to be mixed with oxygen-rich blood in the descending aorta **240**. Because the descending aorta **240** supplies blood to the legs, the oxygen saturation readings at the foot will be lowered accordingly. That is, duct-dependent CHD may be manifested as a higher arterial oxygen saturation measured at a right hand tissue site (reference) and a lower oxygen saturation measured at a foot tissue site.

A PDA also allows a transitory left to right flow during systole, which distends the main pulmonary artery **280** as the result of the blood flow pressure at one end from the right ventricle and at the other end from the aortic arch **290**. A left-to-right flow through the shunt **230** into the distended artery **280** alters the flow in the descending aorta **240** and, as a result, plethysmograph features measured at either foot. Duct-dependent CHD, therefore, may also be manifested as a plethysmograph with a narrow peak and possibly a well-defined dirotic notch at a hand baseline site and a broadened peak and possibly no notch at a foot site.

Further shown in FIG. 2, a left hand has blood circulating from the left ventricle through the left subclavian artery **270** that supplies the left arm. Because the left subclavian artery **270** is nearer a PDA **230** than the further upstream innominate artery **260**, it may experience some mixing of deoxygenated blood and an alteration in flow due to the PDA **230**. Duct-dependent CHD, therefore, may also be manifested as a reduced saturation and an altered plethysmograph wave-

form measured at a left hand tissue site as compared with the right hand baseline site, although to a lesser degree than with a foot site.

FIG. 3 illustrates a patient monitoring system 300, which provides blood parameter measurements, such as arterial oxygen saturation, and which can be adapted as an advantageous diagnostic tool for duct-dependent CHD. The patient monitoring system 300 has a patient monitor 302 and a sensor 306. The sensor 306 attaches to a tissue site and includes a plurality of emitters 322 capable of irradiating a tissue site 320 with differing wavelengths of light, such as the red and infrared wavelengths utilized in pulse oximeters. The sensor 306 also includes one or more detectors 324 capable of detecting the light after attenuation by the tissue 320. A sensor is disclosed in U.S. application Ser. No. 11,367,013, filed on Mar. 1, 2006, titled Multiple Wavelength Sensor Emitters, which is incorporated by reference herein. Sensors that attach to a tissue site and include light emitters capable of irradiating a tissue site with at least red and infrared wavelengths are disclosed in one or more of U.S. Pat. Nos. 5,638,818, 5,782,757, 6,285,896, 6,377,829, 6,760,607, 6,934,570, 6,985,764 and 7,027,849, incorporated by reference herein. Moreover, low noise optical sensors are available from Masimo Corporation, Irvine, Calif.

As shown in FIG. 3, the patient monitor 302 communicates with the sensor 306 to receive one or more intensity signals indicative of one or more physiological parameters and displays the parameter values. Drivers 310 convert digital control signals into analog drive signals capable of driving sensor emitters 322. A front-end 312 converts composite analog intensity signal(s) from light sensitive detector(s) 324 into digital data 342 input to the DSP 340. The DSP 340 may comprise a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In an embodiment, the DSP executes the CHD screening and analysis processes described with respect to FIGS. 7-9, below.

The instrument manager 360 may comprise one or more microcontrollers controlling system management, such as monitoring the activity of the DSP 340. The instrument manager 360 also has an input/output (I/O) port 368 that provides a user and/or device interface for communicating with the monitor 302. In an embodiment, the I/O port 368 provides threshold settings via a user keypad, network, computer or similar device, as described below.

Also shown in FIG. 3 are one or more devices 380 including a display 382, an audible indicator 384 and a user input 388. The display 382 is capable of displaying indicia representative of calculated physiological parameters such as one or more of a pulse rate (PR), plethysmograph (pleth) morphology, perfusion index (PI), signal quality and values of blood constituents in body tissue, including for example, oxygen saturation ( $\text{SpO}_2$ ), carboxyhemoglobin ( $\text{HbCO}$ ) and methemoglobin ( $\text{HbMet}$ ). The monitor 302 may also be capable of storing or displaying historical or trending data related to one or more of the measured parameters or combinations of the measured parameters. The monitor 302 may also provide a trigger for the audible indicator 384 for beeps, tones and alarms, for example. Displays 382 include for example readouts, colored lights or graphics generated by LEDs, LCDs or CRTs to name a few. Audible indicators 384 include, for example, tones, beeps or alarms generated by speakers or other audio transducers to name a few. The user input device 388 may include, for example, a keypad, touch screen, pointing device, voice recognition device, or the like.

A patient monitor is disclosed in U.S. application Ser. No. 11,367,033, filed on Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, incorporated by reference herein. Pulse oximeters capable of measuring physiological parameters including  $\text{SpO}_2$ , pleth, perfusion index and signal quality are disclosed in one or more of U.S. Pat. Nos. 6,770,028, 6,658,276, 6,157,850, 6,002,952, and 5,769,785, incorporated by reference herein. Moreover, pulse oximeters capable of reading through motion induced noise are available from Masimo Corporation, Irvine, Calif.

A congenital heart disease (CHD) monitor advantageously utilizes a patient monitor capable of providing multiple-site blood parameter measurements, such as oxygen saturation, so as to detect, for example, hand-foot oxygen saturation differences associated with a PDA and related CHD.

One aspect of a CHD monitor is a sensor, a patient monitor and a DSP. The sensor is configured to emit optical radiation having a plurality of wavelengths into a tissue site and to detect the optical radiation after attenuation by pulsatile blood flowing within the tissue site. The monitor is configured to drive the sensor, receive a sensor signal corresponding to the detected optical radiation and to generate at least one of a visual output and an audio output responsive to the sensor signal. The DSP is a portion of the patient monitor and is programmed to derive a physiological parameter from sensor data responsive to the sensor signal. The physiological parameter is measured at a baseline tissue site and a comparison tissue site. The outputs indicate a potential CHD condition according to a difference between the physiological parameter measured at the baseline tissue site and the physiological parameter measured at the comparison tissue site.

Another aspect of a CHD monitor is a congenital heart disease screening method providing a patient monitor and corresponding sensor. The sensor is capable of emitting optical radiation having a plurality of wavelengths into a tissue site and detecting the optical radiation after attenuation by pulsatile blood flowing within the tissue site. The patient monitor is capable of receiving a sensor signal corresponding to the detected optical radiation and calculating a blood-related physiological parameter. The physiological parameter is measured at a baseline tissue site and a comparison tissue site. The measured physiological parameter at the baseline tissue site and at the comparison tissue site are compared. A potential CHD condition is indicated based upon the comparison.

A further aspect of a CHD monitor is a detection method determining a plurality of metrics responsive to sensor data derived from a plurality of tissue sites on an infant, testing the metrics with respect to predetermined rules and thresholds, and outputting diagnostics responsive to the test results. The metrics are at least one of a physiological parameter measurement, a cross-channel measurement and a trend. The diagnostics are responsive to the likelihood of congenital heart disease.

Yet another aspect of a CHD monitor comprises a patient monitor, a pre-processor means, an analyzer means and a post-processor means. The patient monitor is configured to receive sensor data from at least one optical sensor attached to a plurality of tissue sites on an infant. The pre-processor means is for deriving at least one metric from the sensor data. The analyzer means is for testing the at least one metric according to at least one rule. The post-processor means is for generating diagnostics based upon results of the testing. The at least one rule defines when the at least one metric indicates a potential CHD condition in the infant.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of a fetal heart depicting a ductus arteriosus;

FIG. 2 is an illustration of a neonatal heart depicting a patent ductus arteriosus (PDA);

FIG. 3 is a general block diagram of a patient monitoring system adapted for congenital heart disease (CHD) detection;

FIG. 4 is an illustration of a single patient monitor utilized for CHD detection;

FIG. 5 is an illustration of multiple patient monitors utilized for CHD detection;

FIG. 6 is an illustration of a single patient monitor and multi-site sensor utilized for CHD detection;

FIGS. 7A-B is a flow diagram of a CHD screening embodiment;

FIG. 8 is a detailed block diagram of a CHD analyzer embodiment; and

FIG. 9 is a detailed block diagram of a preprocessor embodiment for a CHD analyzer.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 4 illustrates CHD detection utilizing a single patient monitor **410** and corresponding sensor **420**. In general, the monitor **410** provides a display or other indicator that directs a caregiver or other user to attach the sensor **420** to an initial tissue site for a first measurement and then to one or more other tissue sites for additional measurements. This procedure is described in further detail with respect to FIGS. 7A-B, below. For example, in a Phase I configuration **401**, the sensor **420** is attached to a neonate's right hand so that the monitor **410** generates baseline site measurements. In a Phase II configuration **402**, the sensor **420** is attached to a neonate's foot so that the monitor **410** generates comparison site measurements. In an optional Phase III configuration **403**, the sensor **420** is attached to a neonate's left hand generating measurements at an additional comparison site. During each phase **401-403**, the monitor **410** takes measurements for a length of time sufficient to determine user-selected parameters, which includes SpO<sub>2</sub> and may include PR, PI, signal quality, pleth morphology, other blood parameters such as HbCO and HbMET, and trends over a selected time interval for any or all of these parameters. In an embodiment, baseline right-hand measurements are made first, followed by measurements at either foot, followed by optional left-hand measurements. In other embodiments, the phase-order of measurements can be user-selected and can be in any order and can include or exclude either the foot or the left-hand measurements.

In an embodiment, a monitor-determined time or user-selectable timer defines how long each site measurement is made, and a monitor display and/or audible indicator signals the user when to switch sensor sites. In an embodiment, a user defines time intervals or times-of-day for making repeat measurement cycles so as to obtain site difference trends. A monitor display and/or audible indicator signals the user when to begin a measurement cycle.

FIG. 5 illustrates CHD detection utilizing multiple patient monitors **510-520** and corresponding sensors **530-540**. In an embodiment, a first monitor **510** and first sensor **530** provide measurements from a right-hand tissue site. A second monitor **520** and second sensor **540** provide measurements from a foot tissue site. An interface cable **550** or wireless link provides communications between the monitors **510-520**.

For example, the monitors **510-520** can communicate respective measurements via RS-232, USB, Firewire or any number of standard wired or wireless communication links. In an embodiment, one monitor, such as the baseline right-hand monitor **510** acts as the master and the comparison (e.g. foot) monitor **520** acts as a slave. The master monitor **510** generates the baseline measurements, transfers the comparison measurements from the slave monitor **520**, calculates the comparison parameters, such as oxygen saturation differences, displays the comparison parameters, calculates alarm conditions based upon the measured and comparison parameters and generates alarms accordingly.

In other embodiments, the comparison site (e.g. foot or left-hand) monitor **520** is the master and the baseline (right-hand) monitor **510** is the slave. In yet another embodiment, there are three networked monitors corresponding to right-hand, left-hand and foot sites, with one monitor acting as a master and the other monitors acting as slaves. The master monitor, in this example, calculates oxygen saturation differences for each pair of sites and generates alarms accordingly.

FIG. 6 illustrates CHD screening utilizing a single CHD patient monitor **610** and a corresponding multi-site sensor **620**. In an embodiment, the multi-site sensor **620** has two sensor heads **622-624** and a common sensor cable **628** for communication with the monitor **610**. One sensor head **622** is attached to a baseline tissue site, e.g. a right-hand and another sensor head **624** is attached to a comparison tissue site, e.g. either a foot or a left-hand. In another embodiment, a third sensor head **626** is available for attachment to a second comparison site, e.g. a left-hand. A multiple site patient monitor is disclosed in U.S. Pat. No. 6,334,065 issued Dec. 25, 2001 titled Stereo Pulse Oximeter which is assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.

FIGS. 7A-B illustrate a CHD screening process **700** corresponding to a single monitor CHD detection embodiment, such as described with respect to FIG. 4, above. In general, the process **700** is described with respect to user actions **701** and monitor responses **702** and, likewise, monitor prompts **702** and user responses **701**. In particular, once the monitor enters a CHD detection mode, the monitor prompts a user to attach the sensor successively to two or more tissue sites. In this manner, the monitor can compute baseline and comparison site measurements and calculate site differences, such as in oxygen saturation, which tend to predict the likelihood or unlikelihood of CHD. In an embodiment, the monitor **702** communicates instructions to the user **701** or otherwise prompts the user with display messages. Alternatively, or in addition to display messages, the monitor **702** can prompt the user via audio messages or indicators, visual indicators such as panel lights or a combination of the above. In an embodiment, the user **701** can trigger the monitor **702** or otherwise respond to monitor **702** prompts via a panel-mounted push button. Alternatively, or in addition to a push button, the user **701** can trigger the monitor **702** or otherwise respond to the monitor **702** via touch screen, touch pad, keyboard, mouse, pointer, voice recognition technology or any similar mechanism used for accomplishing a computer-human interface.

As shown in FIG. 7A, a user **701** initiates CHD screening **705** and the monitor **702** enters a CHD detection mode **710** in response. The monitor **702** then prompts the user **701** to attach a sensor to a baseline site **715**. In response, the user **701** attaches a sensor to a first tissue site **720**, such as a neonate's right hand, and pushes a button **725** to trigger the monitor to take baseline sensor measurements **730**. The

monitor **702** displays the resulting baseline measurements **732** and prompts the user **701** to reattach the sensor to a comparison site **735**. In response, the user **701** removes the sensor and reattaches it to a second tissue site **740**, such as either of a neonate's feet, and pushes a button **745** to trigger the monitor **702** to take comparison sensor measurements **750**. The monitor **702** displays the resulting comparison site measurements **755**.

As shown in FIG. 7B, after taking baseline site and comparison site measurements, the monitor **702** determines if a third site measurement is to be taken **760**. If so, the monitor **702** prompts the user **701** to reattach the sensor to an additional comparison site **765**. In response, the user **701** removes the sensor and reattaches it to a third tissue site **770**, such as a neonate's left-hand, and pushes a button **775** to trigger the monitor **702** to take additional comparison site measurements **780**. The monitor **702** then displays the resulting measurements **785**. The monitor **702** determines if trend measurements are being made **787**. If so, then after a predetermined delay the monitor **702** prompts the user to re-attach the sensor at the baseline site **715** (FIG. 7A) to begin an additional series of measurements **730-785**.

Also shown in FIG. 7B, after all site measurements are taken, the monitor **702** calculates the measurement differences between the baseline and comparison site(s) **790**, calculates trends in measurements and measurement differences **790** and displays the results **792**. The monitor **702** then determines whether any site measurements, site measurement differences or trends are outside of preset limits **794**. If limits are exceeded, the monitor generates visual and/or audio indicators of a potential CHD condition **796**. For example, an audio alert or alarm of a potential CHD condition may be a low-level intermittent beep so as to indicate a diagnostic result and not be confused with other urgent care alarms. In one embodiment, if neonatal SpO<sub>2</sub> measurements from both a right hand and a foot are less than about 95% or a hand-foot difference is greater than about  $\pm 3\%$ , the monitor generates one or more indicators alerting a caregiver that a potential CHD condition exists.

FIG. 8 illustrates a CHD analyzer **800** that executes in the DSP **340** (FIG. 3) and indicates a potential CHD or lack thereof. The CHD analyzer **800** is advantageously responsive to multiple channels of sensor data **801** so as to generate CHD diagnostics **803**. In an embodiment, the CHD analyzer **800** executes the CHD screening process described with respect to FIGS. 7A-B, above, receiving sensor data **342** (FIG. 3) derived from one tissue site at a time. In another embodiment, the CHD analyzer **800** receives sensor data **342** (FIG. 3) derived from two or more sensor sites at a time, such as described with respect to FIGS. 5-6, above. The diagnostic output **803** can be used, for example, to generate displays or indicators useful for grading a neonate with respect to a potential CHD condition and the severity of that condition. In an embodiment, an instrument manager **360** (FIG. 3) convert CHD diagnostics **803** via a display driver **362** (FIG. 3) and an audio driver **364** (FIG. 3) into one or more displays **382** (FIG. 3) and audible indicators **384** (FIG. 3) for use by a physician, clinician, nurse or other caregiver.

In an embodiment, the CHD analyzer **800** has a pre-processor **900**, a metric analyzer **820**, a post-processor **830** and a controller **840**. The pre-processor **900** has sensor data inputs **801** from one or more sensor channels, such as described with respect to FIGS. 4-6, above. The pre-processor **900** generates metrics **822** that may include, for example, physiological parameters, waveform features, and cross-channel comparisons and trends, as described in further detail with respect to FIG. 9, below.

As shown in FIG. 8, the metric analyzer **820** is configured to test metrics **822** and communicate the test results **824** to the post-processor **830** based upon various rules applied to the metrics **822** in view of various thresholds **826**. As an example, the metric analyzer **820** may communicate to the post-processor **830** when a parameter measurement increases faster than a predetermined rate, e.g. a trend metric exceeds a predetermined trend threshold.

Also shown in FIG. 8, the post processor **830** inputs test results **824** and generates CHD diagnostic outputs **803** based upon output definitions **832**. For example, if the test result is that a trend metric exceeds a trend threshold, then the output definition corresponding to that test result may be to trigger an audible alarm. Thresholds, rules, tests and corresponding outputs are described in further detail with respect to TABLE 1, below.

Further shown in FIG. 8, the controller **840** has an external communications port **805** that provides predetermined thresholds, which the controller **840** transmits to the metric analyzer **820**. The controller **840** may also provide metric definitions **824** to the pre-processor **900** and define outputs **832** for the post-processor **830**.

In an embodiment, CHD screening grades a neonate with respect to a likelihood of a CHD condition utilizing green, yellow and red indicators. For example, a green panel light signals that no metric indicates a potential CHD condition exists. A yellow panel light signals that one metric indicates a potential CHD condition exists. A red panel light signals that more than one metric indicates that a potential CHD condition exists. In an embodiment, the CHD analyzer **800** provides a diagnostic output **803** according to TABLE 1, below. The terms Sat<sub>xy</sub>,  $\Delta$ Sat<sub>xy</sub>, and  $\Delta$ t listed in TABLE 1 are described with respect to FIG. 9, below. Various other indicators, alarms, controls and diagnostics in response to various combinations of parameters and thresholds can be substituted for, or added to, the rule-based outputs illustrated in TABLE 1.

TABLE 1

CHD Analyzer Rules and Outputs	
RULE	OUTPUT
If Sat > Sat limit threshold (all channels); Sat <sub>xy</sub> < Sat <sub>xy</sub> limit threshold (all cross-channels); and $\Delta$ Sat <sub>xy</sub> / $\Delta$ t < Sat <sub>xy</sub> trend threshold (all cross-channels).	Then illuminate green indicator.
If Sat < Sat limit threshold (any channel); Sat <sub>xy</sub> > Sat <sub>xy</sub> limit threshold (any cross-channel); or $\Delta$ Sat <sub>xy</sub> / $\Delta$ t > Sat <sub>xy</sub> trend threshold (any cross-channel).	Then illuminate yellow indicator
If Sat < Sat limit threshold (any channel); and Sat <sub>xy</sub> > Sat <sub>xy</sub> limit threshold (any cross-channel).	Then illuminate red indicator
If Sat < Sat limit threshold (any channel); and $\Delta$ Sat <sub>xy</sub> / $\Delta$ t > Sat <sub>xy</sub> trend threshold (any cross-channel).	Then illuminate red indicator

FIG. 9 illustrates a preprocessor embodiment **900** that inputs sensor data **801** derived from one or more tissue sites and outputs metrics **822**. The preprocessor **900** has a parameter calculator **910**, a waveform processor **920**, a cross-channel calculator **930** and a trending function **940**. The parameter calculator **910** outputs one or more physiological parameters derived from pulsatile blood flow at a tissue site. These parameters may include, as examples, arterial oxygen saturation (SpaO<sub>2</sub>), venous oxygen saturation (SpvO<sub>2</sub>), PR

and PI to name a few. In an embodiment, the parameter calculator **910** generates one or more of these parameters for each sensor data channel. The waveform processor **920** extracts various plethysmograph features for each data channel. These features may include, for example, the area under the peripheral flow curve, the slope of the inflow phase, the slope of the outflow phase, the value of the end diastolic baseline and the size and location of the dicrotic notch. The cross-channel calculator **930** generates cross-channel values, such as  $S_{xy} = SpO_2$  (baseline site)  $- SpO_2$  (comparison site). In an embodiment, the calculator **930** can also generate same-channel values, such as  $SpaO_2 - SpvO_2$  from the same sensor site. The trending function **940** calculates trends from the parameter calculator **910**, the waveform processor **920** or the cross-channel calculator **930**. The trending function **940** stores historical values and compares these with present values. This comparison may include  $\Delta p / \Delta t$ , the change in a parameter over a specified time interval, which may also be expressed as a percentage change over that interval. An example is  $\Delta Sat_{t_1} / \Delta t$ , the change in the oxygen saturation difference between two tissue sites over a specified time interval.

Although described above with respect to optical sensor inputs responsive to pulsatile blood flow, in an embodiment, the CHD monitor may include sensor inputs and corresponding algorithms and processes for other parameters such as ECG, EEG,  $ETCO_2$ , respiration rate and temperature to name a few. Although a CHD analyzer is described above as a program executed by a patient monitor DSP, the CHD analyzer can be, in whole or in part, hardware, firmware or software or a combination functioning in conjunction with or separate from the DSP. Further, the CHD analyzer can be configured, in whole or in part, as logic circuits, gate arrays, neural networks or an expert system, as examples. In an embodiment, a CHD monitor, such as described above, for example, as incorporating a patient monitor, CHD analyzer and corresponding CHD screening process, is marketed with instructions on grading a neonate, infant or patient with respect to the likelihood of a CHD condition.

A congenital heart disease monitor has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the present invention, which is defined by the claims that follow. One of ordinary skill in the art will appreciate many variations and modification.

What is claimed is:

1. A congenital heart disease monitor comprising:  
a display;

a sensor configured to emit optical radiation having a plurality of wavelengths into a tissue site and to detect the optical radiation after attenuation by pulsatile blood flowing within the tissue site;

a patient monitor configured to drive the sensor, receive a sensor signal corresponding to the detected optical radiation and to generate at least one of a visual output and an audio output responsive to the sensor signal;  
one or more hardware processors within the patient monitor programmed to derive a physiological parameter measurement comprising oxygen saturation from sensor data responsive to the sensor signal and determine an indication of a congenital heart disease condition for output to the display, the one or more hardware processors further configured to:

electronically determine a first oxygen saturation from a first channel corresponding to a first measurement site;

electronically determine a second oxygen saturation from a second channel at a second measurement site;  
electronically determine a difference of oxygen saturation between the first channel and the second channel;

electronically determine a rate of change of the difference of oxygen saturation over time between the first channel and the second channel; and

electronically determine a first metric based on a comparison of the first oxygen saturation corresponding to the first channel with a saturation limit threshold;

electronically determine a second metric based on a comparison of the second oxygen saturation corresponding to the second channel with the saturation limit threshold;

electronically determine a third metric based on a comparison of the difference of oxygen saturation with a cross channel saturation limit threshold;

electronically determine a fourth metric based on a comparison of the rate of change of the difference of oxygen saturation over time between the first channel and the second channel with a cross channel saturation trend threshold;

electronically generate a first indicator based on the following electronic determinations: the first metric indicating that the first oxygen saturation is greater than the saturation limit threshold, the second metric indicating that the second oxygen saturation is greater than the saturation limit threshold, the third metric indicating that the difference of oxygen saturation is less than the cross channel saturation limit threshold, and the fourth metric indicating that the comparison of the rate of change of the difference is less than the cross channel saturation threshold; and  
electronically generate a second indicator based on the following electronic determinations: the first metric indicating that the first oxygen saturation is greater than the saturation limit threshold or the second metric indicating that the second oxygen saturation is greater than the saturation limit threshold, the first indicator corresponding to a lower risk of congenital heart disease than the second indicator.

2. The congenital heart disease monitor of claim 1, wherein the first indicator comprises a first color and the second indicator comprises a second color different from the first color.

3. The congenital heart disease monitor of claim 1, wherein the rate of change of the difference over time comprises a percentage change over a time interval.

4. The congenital heart disease monitor of claim 1, wherein the one or more hardware processors is further configured to determine that trend data is acquired and generate an indicator to change location of the sensor after determining that the trend data is acquired.

5. The congenital heart disease monitor of claim 1, wherein the first indicator or the second indicator comprises an audio alarm.

6. A congenital heart disease screening method comprising the steps of:

electronically measuring, using a sensor and a patient monitor, a first oxygen saturation at a first patient site;  
electronically measuring, using the sensor and the patient monitor, a second oxygen saturation at the second patient site;

electronically determining a difference between the first oxygen saturation and the second oxygen saturation;

## 11

electronically determining a rate of change of the difference over time;  
 electronically determining a first metric based on a comparison of the first oxygen saturation with a saturation limit threshold;  
 electronically determining a second metric based on a comparison of the second oxygen saturation with the saturation limit threshold;  
 electronically determining a third metric based on a comparison of the difference with a cross channel saturation limit threshold;  
 electronically determining a fourth metric based on a comparison of the rate of change of the difference over time with a cross channel saturation trend threshold;  
 electronically generating a first indicator based on the following electronic determinations: the first metric indicating that the first oxygen saturation is greater than the saturation limit threshold, the second metric indicating that the second oxygen saturation is greater than the saturation limit threshold, the third metric indicating that the difference of oxygen saturation is less than the cross channel saturation limit threshold, and the fourth metric indicating that the comparison of the rate of change of the difference is less than the cross channel saturation threshold; and  
 electronically generating a second indicator based on the following electronic determinations: the first metric

## 12

indicating that the first oxygen saturation is greater than the saturation limit threshold or the second metric indicating that the second oxygen saturation is greater than the saturation limit threshold, the first indicator corresponding to a lower risk of congenital heart disease than the second indicator; and

displaying the generated first indicator or the second indicator on a display screen.

7. The congenital heart disease screening method according to claim 6, comprising the further step of prompting the successive attachment of the sensor to the first site and the second site.

8. The congenital heart disease screening method of claim 6, wherein the first indicator comprises a first color and the second indicator comprises a second color different from the first color.

9. The congenital heart disease screening method of claim 6, wherein the rate of change of the difference over time comprises a percentage change over a time interval.

10. The congenital heart disease screening method of claim 6, further comprising determining that trend data is acquired and generating an indicator to change location of the sensor after determining that the trend data is acquired.

11. The congenital heart disease screening method of claim 6, wherein the first indicator or the second indicator comprises an audio alarm.

\* \* \* \* \*

专利名称(译)	先天性心脏病监测仪		
公开(公告)号	<a href="#">US9687160</a>	公开(公告)日	2017-06-27
申请号	US13/907638	申请日	2013-05-31
[标]申请(专利权)人(译)	梅西莫股份有限公司		
申请(专利权)人(译)	Masimo公司		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	KIANI MASSI JOE E		
发明人	KIANI, MASSI JOE E.		
IPC分类号	A61B5/1455 A61B5/024 A61B5/0205 A61B5/00		
CPC分类号	A61B5/0205 A61B5/02416 A61B5/14551 A61B5/6826 A61B5/6829 A61B5/6838 A61B5/7275 A61B5/7278 A61B5/7282 A61B5/742 A61B5/02055 A61B2560/0276 G16H50/20 G16H50/30		
优先权	60/846160 2006-09-20 US		
其他公开文献	US20130331670A1		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

#### 摘要(译)

先天性心脏病监测器利用能够将多个波长的光辐射发射到组织部位并且在组织部位内流动的脉动血液衰减后检测光辐射的传感器。患者监测器能够接收与检测到的光辐射相对应的传感器信号并且响应地计算至少一个生理参数。在基线位点和比较位点测量生理参数，并计算这些测量值的差异。根据在每个部位测量的生理参数或在部位之间或两者之间测量的生理参数的计算差异来指示潜在的先天性心脏病状况。

